Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Cambridge

Loke CTR Annual Meeting 2025

The 2025 Loke CTR Annual Meeting, themed “The Placenta at Term,” will gather leading clinical and research experts to discuss key topics such as placental [...]

Go to Top